TY - JOUR
T1 - Inhibition of spinal p38 MAPK prevents articular neutrophil infiltration in experimental arthritis via sympathetic activation
AU - Kanashiro, Alexandre
AU - Franchin, Marcelo
AU - Bassi, Gabriel Shimizu
AU - Reis Santana, Dênis Augusto
AU - Cunha, Thiago Mattar
AU - Cunha, Fernando Queiróz
AU - Ulloa, Luis
AU - Rodrigues, Gerson Jonathan
N1 - Funding Information:
The research leading to these results received funding from the Funda©cão de Amparo à Pesquisa do Estado de São Paulo (FAPESP, grants 2011/20343-4, 2013/ 08216-2 and 2012/04237-2), from the National Council for Scientific and Technological Development (CNPq, grant 150718/2010-1, 478504/2010-1 and 142068/ 2012-8). The authors thank Ieda R. Santos, Sérgio R. Rosa and Giuliana Bertozi for technical assistance.
Publisher Copyright:
© 2017 Société Française de Pharmacologie et de Thérapeutique
PY - 2018/4
Y1 - 2018/4
N2 - The central nervous system controls the innate immunity by modulating efferent neuronal networks. Recently, we have reported that central brain stimulation inhibits inflammatory responses. In the present study, we investigate whether spinal p38 mitogen-activated protein kinase (MAPK) affects joint inflammation in experimental arthritis. Firstly, we observed that intra-articular administration of zymosan in mice induces the phosphorylation of the spinal cord p38 MAPK. In addition, we demonstrated that spinal p38 MAPK inhibition with intrathecal injection of SB203580, a conventional and well-characterized inhibitor, prevents knee joint neutrophil recruitment, edema formation, experimental score and cytokine production. This local anti-inflammatory effect was completely abolished with chemical sympathectomy (guanethidine) and beta-adrenergic receptors blockade (nadolol). In conclusion, our results suggest that pharmacological strategies involving the modulation of spinal p38 MAPK circuit can prevent joint inflammation via sympathetic networks and beta-adrenoceptors activation.
AB - The central nervous system controls the innate immunity by modulating efferent neuronal networks. Recently, we have reported that central brain stimulation inhibits inflammatory responses. In the present study, we investigate whether spinal p38 mitogen-activated protein kinase (MAPK) affects joint inflammation in experimental arthritis. Firstly, we observed that intra-articular administration of zymosan in mice induces the phosphorylation of the spinal cord p38 MAPK. In addition, we demonstrated that spinal p38 MAPK inhibition with intrathecal injection of SB203580, a conventional and well-characterized inhibitor, prevents knee joint neutrophil recruitment, edema formation, experimental score and cytokine production. This local anti-inflammatory effect was completely abolished with chemical sympathectomy (guanethidine) and beta-adrenergic receptors blockade (nadolol). In conclusion, our results suggest that pharmacological strategies involving the modulation of spinal p38 MAPK circuit can prevent joint inflammation via sympathetic networks and beta-adrenoceptors activation.
KW - arthritis
KW - beta-adrenergic receptors
KW - neuroimmunomodulation
KW - neutrophil
KW - p38 MAPK
KW - sympathetic nervous system
UR - http://www.scopus.com/inward/record.url?scp=85038878898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038878898&partnerID=8YFLogxK
U2 - 10.1111/fcp.12338
DO - 10.1111/fcp.12338
M3 - Article
C2 - 29206314
AN - SCOPUS:85038878898
SN - 0767-3981
VL - 32
SP - 155
EP - 162
JO - Fundamental and Clinical Pharmacology
JF - Fundamental and Clinical Pharmacology
IS - 2
ER -